West Announces First-Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
West Pharma (WST) Tops Q1 EPS by 62c, Revenues Beat; Offers FY21 EPS/Revenues Guidance Above Consensus
April 29, 2021 6:14 AM EDTWest Pharma (NYSE: WST) reported Q1 EPS of $2.05, $0.62 better than the analyst estimate of $1.43. Revenue for the quarter came in at $670.7 million versus the consensus estimate of $611.39 million.
First-Quarter 2021 Summary (comparisons to prior-year period)
Net sales of $670.7 million grew 36.5%; organic sales growth was 31.1%.Reported-diluted EPS of $1.99 increased 101%.Adjusted-diluted EPS of $2.05 increased 103%.The Company is raising full-year 2021 net sales guidance to a new range of $2.630 billion to $2.655 billion, compared to a prior range of $2.500 billion to $2.525 billion. The Company is raising full-year 2021 adjusted-diluted EPS guidance to a new... More